CXCR3 Protein

CXCR3 Protein — C-X-C Motif Chemokine Receptor 3

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CXCR3 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>C-X-C Motif Chemokine Receptor 3 (CXCR3)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[CXCR3](/genes/cxcr3)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P49682" target="_blank">P49682</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~40 kDa (glycosylated), ~35 kDa (core)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane (GPCR), intracellular pools</td></tr>
<tr><td><strong>Protein Family</strong></td><td>CXC chemokine receptor family (Class A GPCR)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>T cells, NK cells, microglia, astrocytes, neurons</td></tr>
<tr><td><strong>Ligands</strong></td><td>CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC)</td></tr>
<tr><td><strong>Signaling</strong></td><td>Gαi/o protein-coupled, β-arrestin recruitment</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas

CXCR3 Protein — C-X-C Motif Chemokine Receptor 3

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CXCR3 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>C-X-C Motif Chemokine Receptor 3 (CXCR3)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[CXCR3](/genes/cxcr3)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P49682" target="_blank">P49682</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~40 kDa (glycosylated), ~35 kDa (core)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane (GPCR), intracellular pools</td></tr>
<tr><td><strong>Protein Family</strong></td><td>CXC chemokine receptor family (Class A GPCR)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>T cells, NK cells, microglia, astrocytes, neurons</td></tr>
<tr><td><strong>Ligands</strong></td><td>CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC)</td></tr>
<tr><td><strong>Signaling</strong></td><td>Gαi/o protein-coupled, β-arrestin recruitment</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">115 edges</a></td>
</tr>
</table>
</div>

Overview

CXCR3 is a seven-transmembrane G protein-coupled receptor (GPCR) that serves as the primary receptor for three interferon-gamma (IFN-γ)-inducible chemokines: CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC)[@gimenez2023]. As a key coordinator of T cell trafficking and immune surveillance, CXCR3 plays a central role in directing effector T cells toward sites of inflammation. In the central nervous system (CNS), the CXCR3/CXCL10 axis is a major driver of neuroinflammation in [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [multiple sclerosis](/diseases/multiple-sclerosis) (MS), and other neurodegenerative conditions[@lacotte2019].

The significance of CXCR3 in neurodegeneration extends beyond its canonical role in T cell recruitment. The receptor is expressed on microglia, astrocytes, and even neurons, where it contributes to disease-specific inflammatory cascades. The elevated expression of its ligands — particularly CXCL10 — in affected brain regions of AD and PD patients, combined with the accumulation of CXCR3+ immune cells in neuropathological lesions, makes the CXCR3/CXCL10 axis one of the most consistently implicated chemokine pathways in neurodegenerative disease[@windsor2024][@chen2023].

Structure and Mechanism

Structure of a Class A GPCR

CXCR3 belongs to the rhodopsin-like (Class A) family of GPCRs, characterized by their seven transmembrane alpha-helices (TM1-TM7) connected by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3)[@zlotnik2017]. The transmembrane domain forms a bundlelike structure with a ligand-binding pocket accessible from the extracellular space. The receptor has:

• N-terminal extracellular domain: Contains sulfated tyrosines that contribute to ligand binding affinity and selectivity
• Seven transmembrane helices: Form the ligand-binding pocket; the DRYLAIV motif at the intracellular end of TM3 is critical for G protein coupling
• C-terminal intracellular domain: Contains serine and threonine residues for G protein-coupled receptor kinase (GRK)-mediated phosphorylation, which regulates β-arrestin binding and receptor desensitization

Ligand Recognition and Signaling

CXCR3 binds three closely related chemokines with different affinities:

| Ligand | Alternative Name | CXCR3 Binding Affinity | Induction |
|--------|-----------------|----------------------|-----------|
| CXCL9 | MIG (Monokine induced by IFN-γ) | Moderate (Kd ~ 1-10 nM) | IFN-γ, IFN-α |
| CXCL10 | IP-10 (Interferon gamma-inducible protein of 10 kDa) | High (Kd ~ 0.1-1 nM) | IFN-γ, IFN-α, TNF-α |
| CXCL11 | I-TAC (Interferon-inducible T cell alpha chemoattractant) | Very high (Kd ~ 0.01-0.1 nM) | IFN-γ, IFN-α |

All three ligands share a common ELR motif-negative CXC chemokine structure and are induced primarily by type I and type II interferons, establishing a direct link between antiviral and anti-tumor immune responses and T cell trafficking[@gimenez2023].

Signaling Pathways

CXCR3 signals exclusively through Gαi/o proteins (predominantly Gαi2), resulting in:

β-arrestin recruitment (arrestin-2/3) is also robust, enabling:

• Receptor desensitization and internalization
• β-arrestin-dependent signal transduction (biased signaling)
• Receptor trafficking to endosomes for sustained signaling

Biological Functions in the Healthy CNS

T Cell Trafficking and Immune Surveillance

In the healthy CNS, a small population of tissue-resident memory T cells (TRM cells) provides immune surveillance against pathogens and tumors. CXCR3 plays a critical role in the recruitment of these cells:

• CD8+ T effector memory cells (TEM): Express high CXCR3 levels, enabling rapid homing to inflamed or infected CNS sites
• CD4+ Th1 cells: CXCR3+ Th1 cells are preferentially recruited during type 1 immune responses
• NK cells: CXCR3 is expressed on NK cell subsets and facilitates their homing to inflamed tissues

Microglial Functions

Microglia express CXCR3 at low levels under normal conditions, where it may participate in:

• Sensing neuronal injury signals
• Modulating microglial process extension toward damaged areas
• Fine-tuning the neuroinflammatory response to infections or trauma

Neuronal Expression

CXCR3 expression has been reported on select neuronal populations, particularly in the hippocampus and cortex. Neuronal CXCR3 signaling may modulate synaptic function and neurogenesis, though this area remains less well-characterized.

Role in Alzheimer's Disease

Evidence from Human Studies

The CXCR3/CXCL10 axis is consistently implicated in AD across multiple lines of evidence[@windsor2024]:

• Post-mortem brain studies: CXCL10 is markedly elevated in AD hippocampus, entorhinal cortex, and prefrontal cortex, particularly in microglia and astrocytes surrounding amyloid plaques. CXCR3+ T cells are found in close proximity to plaques, suggesting active recruitment
• CSF biomarkers: CXCL10 is significantly elevated in AD patient CSF compared to age-matched controls, and higher levels correlate with more advanced disease (higher Braak stage, lower MMSE scores) and faster cognitive decline[@wang2024]
• Blood biomarkers: Peripheral blood CXCR3+ T cell frequency is elevated in AD patients, particularly the CXCR3+ CD8+ TEMRA (terminally differentiated) population
• Genetic studies: CXCR3 polymorphisms have been associated with AD risk in some cohorts, though findings are not universally consistent

Mechanisms in AD Pathogenesis

Adaptive Immunity and T Cell Infiltration

CXCR3 mediates the recruitment of peripheral T cells into the AD brain through the [blood-brain barrier](/entities/blood-brain-barrier)[@gimenez2023]. IFN-γ-producing CXCR3+ T cells (predominantly CD8+ TEM and CD4+ Th1 subsets) traffic into the CNS in response to CXCL10 gradients emanating from activated microglia and astrocytes surrounding amyloid plaques. This adaptive immune infiltration contributes to:

• Chronic neuroinflammation through cytokine production by infiltrating T cells
• Direct cytotoxic effects on neurons (particularly CD8+ cytotoxic T lymphocytes)
• Amplification of microglial activation through IFN-γ and other T cell cytokines

Microglial CXCR3 Signaling

CXCR3 expression on microglia is upregulated by IFN-γ and by amyloid-beta exposure itself[@koh2023]. Microglial CXCR3 activation by CXCL10:

• Promotes a pro-inflammatory (M1-like) microglial phenotype
• Induces production of TNF-α, IL-1β, and IL-6
• Enhances production of additional CXCL10 (creating a feed-forward loop)
• May impair amyloid phagocytosis and clearance
• Contributes to synaptic pruning dysfunction

Relationship to Amyloid and Tau Pathology

CXCR3/CXCL10 signaling intersects with both major AD pathological hallmarks:

• Amyloid: CXCL10 is induced by amyloid deposits and contributes to microglial activation around plaques. CXCR3+ T cells may attempt to recognize amyloid-related antigens or respond to local inflammation
• Tau: CXCR3 activation may contribute to tau pathology through microglia-driven neuroinflammation, which activates tau kinases (GSK-3β, CDK5). Additionally, CXCR3+ T cells may damage neurons bearing tau pathology, releasing intracellular contents that further amplify inflammation

Synaptic Dysfunction

Infiltrating CXCR3+ T cells and activated microglia produce factors that impair synaptic function:

• IFN-γ and TNF-α from T cells suppress [NMDA receptor](/entities/nmda-receptor) function
• IL-1β from activated microglia blocks [long-term potentiation](/mechanisms/long-term-potentiation) (LTP)
• CXCL10 itself may have direct effects on synaptic plasticity

Therapeutic Targeting in AD

Several approaches targeting the CXCR3/CXCL10 axis are in development[@bailey2024]:

• CXCR3 antagonists: Small molecule antagonists (e.g., AMG 487, T confluence) block CXCR3 signaling and reduce T cell infiltration and microglial activation in animal models
• CXCL10 neutralizing antibodies: Reduce neuroinflammation and improve outcomes in AD mouse models
• CXCR3 decoy receptors: Engineered CXCR3-Fc fusion proteins that sequester CXCL9/10/11
• Kinase inhibitors: Janus kinase (JAK) inhibitors reduce IFN-γ-driven CXCL10 induction upstream

Role in Parkinson's Disease

Evidence from Human Studies

CXCR3+ immune cells are prominent in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) of PD patients, and the CXCR3/CXCL10 axis is strongly implicated in dopaminergic neurodegeneration[@chen2023]:

• Post-mortem studies: CXCL10 is markedly elevated in the substantia nigra of PD patients, particularly in activated microglia and astrocytes. CXCR3+ CD8+ T cells are found infiltrating the parenchyma and around melanized dopaminergic neurons
• CSF studies: PD patients show elevated CSF CXCL10, which correlates with disease severity (UPDRS scores) and progression rate
• Blood studies: CXCR3+ CD8+ T cells are expanded in PD blood and show evidence of activation (HLA-DR+, PD-1+)

Mechanisms in PD Pathogenesis

T Cell-Mediated Dopaminergic Neurodegeneration

CXCR3+ CD8+ T cells infiltrate the substantia nigra in response to CXCL10 gradients and contribute directly to dopaminergic neuron death[@chen2023]:

• CD8+ T cells release granzyme B and perforin, which are directly cytotoxic to dopaminergic neurons
• IFN-γ from CXCR3+ Th1 cells activates microglia and astrocytes, amplifying the inflammatory cascade
• T cells specific for α-synuclein epitopes may be preferentially recruited via CXCR3, representing a potential autoimmune component of PD

CXCR3 Deficiency Studies

A landmark study used CXCR3-deficient mice to demonstrate that CXCR3 deletion dramatically accelerates [alpha-synuclein](/proteins/alpha-synuclein) pathology and dopaminergic degeneration in a mouse model of PD (alpha-synuclein pre-formed fibril injection)[@chen2019]. This surprising result — that removing the receptor paradoxically worsens disease — suggests that:

• CXCR3 signaling may have protective functions in some contexts (perhaps related to regulatory T cell recruitment or amyloid clearance)
• The CXCR3/CXCL10 axis has complex, context-dependent roles that may vary by disease stage
• Global blockade of CXCR3 may not be a straightforward therapeutic strategy in PD

Microglial and Astrocyte Activation

CXCR3 signaling on nigral microglia drives their activation and neurotoxic mediator production. CXCL10 treatment of microglial cultures induces production of TNF-α, IL-1β, and nitric oxide (NO), all of which are directly toxic to dopaminergic neurons. Astrocytes also express CXCR3, and activation drives their reactive phenotype, reducing their neuroprotective supportive functions.

Therapeutic Challenges in PD

The contradictory results from CXCR3 deletion (accelerated pathology in some models) suggest that:

• CXCR3 may have both pathogenic and protective roles depending on context
• The relative contributions may shift across disease stages
• Cell-type-specific targeting may be needed (e.g., blocking on T cells while preserving microglial functions)
• Further research is needed before CXCR3 blockade can be pursued in PD

Role in Multiple Sclerosis

The CXCR3/CXCL10 axis is one of the most well-established therapeutic targets in MS[@reijerkerk2022]:

• CXCL10 is highly expressed in MS lesions and CSF, and CXCR3+ T cells (particularly Th1 cells) are the predominant infiltrating subset
• CXCR3 is a key driver of T cell trafficking across the BBB into the CNS in MS
• CXCR3 antagonism reduces disease severity in EAE (the animal model of MS)
• CXCR3 is used as a biomarker for MS disease activity and treatment response
• Several CXCR3 antagonists have been in clinical trials for MS (notably, results have been mixed, suggesting timing and patient selection are critical)

Role in Amyotrophic Lateral Sclerosis (ALS)

In ALS, CXCR3+ T cells are found in spinal cord lesions, and their frequency correlates with disease progression rate[@park2023]:

• CXCL10 is elevated in ALS patient CSF and spinal cord tissue
• CXCR3+ T cells may contribute to motor neuron injury through cytotoxic mechanisms and inflammatory amplification
• CXCR3 expression is detected on astrocytes in ALS spinal cord, where it may contribute to astrogliosis

Role in Traumatic Brain Injury (TBI)

CXCR3 contributes to secondary injury following TBI through excessive T cell infiltration and neuroinflammation[@yang2022]:

• CXCL10 is rapidly elevated in the injured brain following TBI
• CXCR3+ T cells infiltrate the damaged CNS, driving neuroinflammation
• CXCR3 antagonists (e.g., AMG 487) reduce post-TBI neuroinflammation, improve motor and cognitive outcomes, and reduce lesion size in animal models
• CXCR3 blockade is particularly effective when given early after injury

Role in Aging and Cognitive Decline

CXCR3/CXCL10 signaling increases with normal aging, contributing to the age-related neuroinflammatory state ("inflammaging")[@rocca2021]:

• Aged brains show elevated baseline CXCL10 and increased CXCR3+ T cell infiltration
• This chronic low-grade inflammation may contribute to age-related cognitive decline
• CXCR3 deficiency or blockade in aged mice improves cognitive function and reduces neuroinflammation
• The CXCR3 axis may be a specific mechanistic link between aging and neurodegenerative disease risk

Signal Transduction Pathway

Therapeutic Target Landscape

| Strategy | Agent | Mechanism | Status |
|----------|-------|-----------|--------|
| CXCR3 antagonist | AMG 487 | Small molecule, competitive inhibition | Preclinical |
| CXCR3 antagonist | T confluence | Small molecule | Preclinical |
| CXCR3 antagonist | Navarixin (SCH 546739) | Small molecule | Phase 2 (asthma, completed) |
| CXCR3 mAb | Ulituximab | Anti-CXCR3 monoclonal antibody | Preclinical oncology |
| CXCL10 mAb | BMS-986253 | Neutralizing anti-CXCL10 | Phase 1/2 (oncology) |
| CXCR3 decoy | CXCR3-Fc | Engineered receptor-Fc fusion | Preclinical |
| JAK inhibitor | Tofacitinib | Reduces CXCL10 induction (upstream) | Rheumatoid arthritis approved |
| JAK inhibitor | Ruxolitinib | Reduces CXCL10 induction (upstream) | Myelofibrosis approved |

Biomarkers

• CSF CXCL10: Marker of CNS interferon-driven inflammation; elevated in AD, PD, MS, ALS
• Blood CXCR3+ T cell count: Correlates with disease activity in MS; elevated in AD and PD
• Soluble CXCR3 (sCXCR3): Shed receptor that may act as a decoy; being evaluated as a disease biomarker

Cross-Links

• [CXCR3 Gene](/genes/cxcr3)
• [CXCL10 Gene](/genes/cxcl10) — the primary ligand in neurodegeneration
• [CXCL9 Gene](/genes/cxcl9) — IFN-γ-inducible ligand
• [CXCL11 Gene](/entities/cxcl11) — highest-affinity ligand
• [Multiple Sclerosis](/diseases/multiple-sclerosis) — where CXCR3 is most implicated
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway) — broader context
• [Microglia in Neurodegeneration](/cell-types/microglia-neuroinflammation) — primary source of CXCL10 in CNS
• [T Cell Trafficking and CNS Entry](/mechanisms/t-cell-trafficking-cns) — CXCR3's primary biological function